Galapagos (NASDAQ:GLPG – Get Rating) had its target price boosted by equities researchers at JPMorgan Chase & Co. from €60.00 ($63.16) to €65.00 ($68.42) in a report issued on Thursday, The Fly reports. The firm currently has a “neutral” rating on the biotechnology company’s stock.
A number of other research firms have also recently commented on GLPG. Zacks Investment Research upgraded Galapagos from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a research note on Wednesday. Morgan Stanley raised their price objective on Galapagos from $77.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, February 28th. Bryan, Garnier & Co raised Galapagos from a “sell” rating to a “buy” rating in a research report on Friday, January 28th. Citigroup raised Galapagos from a “neutral” rating to a “buy” rating in a research report on Thursday, January 27th. Finally, StockNews.com initiated coverage on Galapagos in a research report on Thursday, March 31st. They set a “hold” rating for the company. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $65.54.
NASDAQ GLPG opened at $59.23 on Thursday. Galapagos has a fifty-two week low of $46.41 and a fifty-two week high of $81.12. The company has a current ratio of 8.44, a quick ratio of 8.55 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $62.76 and a two-hundred day simple moving average of $58.67.
About Galapagos (Get Rating)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.